Susquehanna Fundamental Investments LLC Buys New Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Susquehanna Fundamental Investments LLC purchased a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 17,108 shares of the biopharmaceutical company’s stock, valued at approximately $1,172,000.

A number of other large investors have also recently made changes to their positions in the company. EFG Asset Management North America Corp. boosted its holdings in shares of Intra-Cellular Therapies by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 34,452 shares of the biopharmaceutical company’s stock valued at $2,357,000 after acquiring an additional 163 shares in the last quarter. Parallel Advisors LLC increased its position in Intra-Cellular Therapies by 16.3% during the 4th quarter. Parallel Advisors LLC now owns 1,564 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 219 shares in the last quarter. Kapitalo Investimentos Ltda acquired a new position in Intra-Cellular Therapies in the 4th quarter valued at about $26,000. Lisanti Capital Growth LLC lifted its holdings in Intra-Cellular Therapies by 0.8% in the 1st quarter. Lisanti Capital Growth LLC now owns 53,285 shares of the biopharmaceutical company’s stock valued at $3,687,000 after purchasing an additional 400 shares in the last quarter. Finally, Tidal Investments LLC grew its stake in Intra-Cellular Therapies by 13.9% in the 1st quarter. Tidal Investments LLC now owns 3,698 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 450 shares during the period. 92.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on ITCI. Canaccord Genuity Group raised their price target on shares of Intra-Cellular Therapies from $107.00 to $113.00 and gave the company a “buy” rating in a report on Thursday, June 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 price target on shares of Intra-Cellular Therapies in a report on Monday, September 16th. Royal Bank of Canada dropped their price objective on Intra-Cellular Therapies from $107.00 to $106.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Piper Sandler upgraded shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $68.00 to $92.00 in a research note on Friday, September 6th. Finally, UBS Group lowered their price objective on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.58.

Insider Activity

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 53,013 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $80,970,388.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Mark Neumann sold 18,714 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $75.08, for a total value of $1,405,047.12. Following the sale, the executive vice president now directly owns 29,700 shares in the company, valued at approximately $2,229,876. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total value of $4,010,433.45. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $80,970,388.85. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 175,316 shares of company stock worth $13,037,345. Company insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock opened at $72.65 on Wednesday. The stock’s 50-day moving average is $75.37 and its two-hundred day moving average is $71.88. Intra-Cellular Therapies, Inc. has a fifty-two week low of $45.50 and a fifty-two week high of $84.89. The firm has a market cap of $7.67 billion, a P/E ratio of -62.63 and a beta of 1.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The business had revenue of $161.40 million for the quarter, compared to the consensus estimate of $157.74 million. During the same period last year, the business earned ($0.45) EPS. The firm’s revenue was up 45.7% compared to the same quarter last year. As a group, research analysts expect that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.